Large-Scale Freezing of Biologics: Understanding Protein and Solute Concentration Changes in a Cryovessel—Part 2 - New data about cryoconcentration behavior at large scale. - BioPharm


Large-Scale Freezing of Biologics: Understanding Protein and Solute Concentration Changes in a Cryovessel—Part 2
New data about cryoconcentration behavior at large scale.

BioPharm International
Volume 23, Issue 7


The results from mapping the frozen state suggest that cryoconcentration is preserved in the frozen state and the observed macro-cryoconcentration values during freezing were in general agreement with frozen state values. The extent of macro-cryoconcentration (measured by cores) varied between the top and bottom halves of the frozen block. The significantly higher macro-cryoconcentration in the lower half of the cryowedge can be explained by the presence of disaccharide in the formulation and formation of temperature-induced density gradients. When freezing a protein solution containing an additive that shows significant changes in density with temperature, a cooling-induced density gradient is created that leads to convective flow of solution. This causes the lower regions of the solution to cryoconcentrate to a greater extent than the upper regions. However, looking fundamentally at the changes occurring during the freezing process tells us that the true extent of (micro-)cryoconcentration experienced by the protein in the inter-dendritic spaces can be estimated from a phase or state diagram for the major solute component. This is significantly higher than what is measured as macro-cryoconcentration. Active freezing systems can affect the overall distribution of ice and solute in the matrix, i.e., the macro-cryoconcentration, but not the micro-cryoconcentration experienced by the solute and protein embedded in the matrix.

Parag Kolhe is a principal scientist, Alanta Lary is a senior scientist, Steven Chico is an associate scientist, Elisabeth Holding was an associate scientist, and Satish K. Singh is a research fellow, all at Pfizer, Inc., Chesterfield, MO, 636.247.9979,


1. Tschoepe M, Schmidt R. Impact of freeze/thaw processing on monoclonal antibody stability. Bioprocess International Conference. Vienna, April 2008.

2. Kolhe P, Badkar A. Protein and solute distribution in drug substance containers during frozen storage as well as post-thawing: a tool to understand and fefine freezing-thawing parameters. Biotechnol Proc Devel. Submitted 2009.

3. Lashmar UT, Vanderburgh M, Little SJ. Bulk Freeze–Thawing of macromolecules: effects of cryoconcentration on their formulation and stability. Bioprocess Int. 2007;5(6):44–54.

4. Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. Freezing biopharmaceutical using common techniques and the magnitude of bulk scale freeze-concentration. Bioprocess Int. 2002;15(5):22–34.

5. Kolhe P, Holding E, Lary A, Chico S, Singh SK. Large-scale freezing of biologics: understanding protein and solute concentration changes in a cryovessel–part I. BioPharm Int. 2010;23(6):53–60.

6. Zippelius R. Untersuchung zum Enifrier- und Aufauverhalten Pharmazeutischer Humanproteinlosungen im Grossmasstab. (Investigation of freezing and thawing process of human pharmaceutical protein solutions at large scale). PhD Thesis (in German), Ludwig-Maximilians University, Munich, 2002.

7. Wisniewski R, Wu VL. Large-Scale Freezing and Thawing of Biopharmaceutical Products. In: Avis KE, Wu VL, ed. Biotechnology and Biopharmaceutical Manufacturing, Processing, and Preservation Vol 2 of Drug manufacturing technology series: CRC Press, 1996:7–60.

8. Muldrew K, Acker JP, Elliott JAW, McGann LE. The water to ice transition: Implications for living cells. In: Fuller BJ, Benson EE, Lane N, editors. Life in the frozen state. Boca Raton, FL. CRC Press; 2004:67–108.

9. Roos Y, Karel M. Applying state diagrams to food processing and development. Food Technol. 1991 Dec;45(12):66, 68–71, 107.

10. Singh SK, Kolhe P, Wang W, Nema S. Large-scale freezing of biologics—a practitioner's review part 1: fundamental aspects. Bioprocess Int. 2009;7(10):32–44.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here